Risk factors for the development of obesity in children surviving brain tumors.
Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors. We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity. Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148). Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy. Analyses were performed both between groups within a risk factor and against BMI changes for age in normal children older than 5.5 yr (the age of adiposity rebound). Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03). In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018). These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors. In particular, hypothalamic radiation doses of more than 51 Gy are permissive. These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.
Lustig
Robert H
RH
Departments of Endocrinology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. rlustig@peds.ucsf.edu
Post
Susan R
SR
Srivannaboon
Kleebsabai
K
Rose
Susan R
SR
Danish
Robert K
RK
Burghen
George A
GA
Xiong
Xiaoping
X
Wu
Shengjie
S
Merchant
Thomas E
TE
D001254:Astrocytoma / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy; D001932:Brain Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D018572:Disease-Free Survival; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D008527:Medulloblastoma / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy; D009765:Obesity / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors